TCM Biotech International Corp. (TPE:4169)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
158.00
+0.50 (0.32%)
At close: Apr 29, 2026
200.38%
Market Cap 9.33B
Revenue (ttm) 685.49M
Net Income (ttm) 19.17M
Shares Out 59.05M
EPS (ttm) 0.32
PE Ratio 486.68
Forward PE n/a
Dividend 0.36 (0.23%)
Ex-Dividend Date n/a
Volume 176,959
Average Volume 553,695
Open 157.50
Previous Close 157.50
Day's Range 156.50 - 163.50
52-Week Range 48.85 - 250.00
Beta 0.21
RSI 42.95
Earnings Date Apr 17, 2026

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabe... [Read more]

Industry Pharmaceutical Preparations
Founded 1998
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 4169
Full Company Profile

Financial Performance

In 2025, TCM Biotech International's revenue was 685.49 million, an increase of 2.84% compared to the previous year's 666.53 million. Earnings were 19.17 million, a decrease of -8.76%.

Financial Statements

News

There is no news available yet.